CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.311
EU - Europa 8.900
AS - Asia 8.821
SA - Sud America 1.369
AF - Africa 268
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 25
Totale 43.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.017
SG - Singapore 2.788
GB - Regno Unito 2.659
CN - Cina 1.859
IT - Italia 1.376
HK - Hong Kong 1.281
VN - Vietnam 1.177
BR - Brasile 1.061
DE - Germania 826
FI - Finlandia 738
SE - Svezia 690
IE - Irlanda 441
UA - Ucraina 432
FR - Francia 399
RU - Federazione Russa 369
PL - Polonia 367
TR - Turchia 362
IN - India 254
ID - Indonesia 198
BG - Bulgaria 190
CA - Canada 155
BD - Bangladesh 135
JP - Giappone 114
IQ - Iraq 101
AR - Argentina 97
KR - Corea 93
MX - Messico 76
EG - Egitto 59
NL - Olanda 55
ES - Italia 54
PK - Pakistan 51
ZA - Sudafrica 50
EC - Ecuador 48
VE - Venezuela 48
MY - Malesia 45
BE - Belgio 43
LT - Lituania 43
AE - Emirati Arabi Uniti 40
MA - Marocco 40
CO - Colombia 35
PH - Filippine 35
AT - Austria 33
NP - Nepal 31
TW - Taiwan 31
UZ - Uzbekistan 31
CL - Cile 27
TN - Tunisia 26
AU - Australia 25
CZ - Repubblica Ceca 25
JO - Giordania 25
SA - Arabia Saudita 25
KE - Kenya 23
RO - Romania 22
CH - Svizzera 20
PY - Paraguay 20
DZ - Algeria 19
IR - Iran 18
EU - Europa 17
MD - Moldavia 16
DO - Repubblica Dominicana 15
TH - Thailandia 15
AZ - Azerbaigian 14
HU - Ungheria 14
IL - Israele 13
PT - Portogallo 13
UY - Uruguay 13
PE - Perù 12
NO - Norvegia 11
SN - Senegal 11
OM - Oman 10
AL - Albania 8
KZ - Kazakistan 8
SY - Repubblica araba siriana 8
BH - Bahrain 7
ET - Etiopia 7
JM - Giamaica 7
NZ - Nuova Zelanda 7
PA - Panama 7
BO - Bolivia 6
DK - Danimarca 6
GH - Ghana 6
HR - Croazia 6
LB - Libano 6
QA - Qatar 6
RS - Serbia 6
AO - Angola 5
CR - Costa Rica 5
CY - Cipro 5
GE - Georgia 5
GR - Grecia 5
HN - Honduras 5
MT - Malta 5
PS - Palestinian Territory 5
SK - Slovacchia (Repubblica Slovacca) 5
TT - Trinidad e Tobago 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CG - Congo 4
KG - Kirghizistan 4
LK - Sri Lanka 4
LU - Lussemburgo 4
Totale 43.647
Salva come PNG Salva come JPEG
Città #
Fairfield 3.220
Ashburn 2.355
Santa Clara 1.839
Woodbridge 1.803
Singapore 1.800
Southend 1.676
Houston 1.462
Seattle 1.266
Hong Kong 1.259
Chandler 1.184
Cambridge 1.022
Wilmington 1.009
Jacksonville 748
Dearborn 736
Ann Arbor 731
San Jose 605
Helsinki 599
Beijing 544
London 489
Nyköping 468
Dublin 434
Warsaw 355
Council Bluffs 336
Modena 313
Ho Chi Minh City 307
The Dalles 291
New York 268
Hanoi 265
Los Angeles 244
San Diego 243
Dallas 241
Izmir 219
Princeton 186
Sofia 186
Lauterbourg 181
Eugene 174
Jakarta 158
Chicago 152
Hefei 132
Milan 127
Shanghai 115
Moscow 114
Buffalo 106
Dong Ket 103
São Paulo 92
Columbus 86
Tokyo 84
Seoul 83
Falls Church 82
Munich 77
Frankfurt am Main 74
Orem 71
Boardman 66
Bremen 63
Da Nang 63
Fremont 63
Salt Lake City 63
Phoenix 57
Redwood City 55
Baghdad 53
Ottawa 47
Guangzhou 46
Bologna 39
Redondo Beach 39
Mumbai 38
Brussels 36
San Giuliano Milanese 36
Rome 35
Atlanta 33
Belo Horizonte 33
Brooklyn 32
Chennai 32
Haiphong 32
Poplar 30
Rio de Janeiro 30
Tampa 30
Norwalk 29
Tashkent 29
Cairo 28
Denver 28
Toronto 28
Miano 26
Turku 25
Brasília 24
Mexico City 23
Nuremberg 23
Dhaka 22
Lawrence 22
Montreal 22
Asyut 21
Düsseldorf 21
Falkenstein 21
Nanjing 21
Johannesburg 20
Kilburn 20
Amman 19
Amsterdam 19
Paris 19
Biên Hòa 18
Chiswick 18
Totale 32.311
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 597
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 581
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 449
GD2 expression in breast cancer. 420
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 417
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 409
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 399
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 396
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 382
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 377
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 374
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 353
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 346
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 345
The evolving role of microsatellite instability in colorectal cancer: A review 332
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 328
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 328
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 328
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 325
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 324
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 321
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 319
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 318
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 317
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 310
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
5-Fluorouracil pharmacogenomics: still rocking after all these years? 308
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 305
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 305
Il trattamento di prima e seconda linea nel carcinoma gastrico 304
Transient sunitinib resistance in gastrointestinal stromal tumors. 300
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 300
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 299
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 299
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 299
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 297
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 297
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 294
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 294
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 293
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 293
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 292
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 286
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 282
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 279
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 277
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 274
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 274
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 273
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 271
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 269
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 267
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 266
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 265
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 264
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 264
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 264
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 262
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 262
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 259
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 259
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 258
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 258
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 256
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 255
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 253
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 250
Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) 250
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 248
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 245
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 245
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 244
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 240
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 239
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 238
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 237
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 236
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 234
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 234
Bone metastases- Pharmacological treatment 233
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 232
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 232
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 230
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 230
The Italian Rare Pancreatic Exocrine Cancer Initiative 230
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) 230
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 229
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 229
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response 229
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 227
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 227
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 226
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 222
Selecting the best treatment for an individual patient. 221
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 220
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. 219
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 219
Progress of molecular targeted therapies for advanced renal cell carcinoma. 218
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 217
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 213
Totale 28.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.562
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 162.562
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021748 0 0 0 0 0 0 0 0 0 0 370 378
2021/20223.523 231 431 327 152 96 237 184 191 373 348 642 311
2022/20233.538 411 357 221 315 409 418 51 283 766 41 148 118
2023/20242.030 76 115 115 190 417 121 250 346 43 53 95 209
2024/20256.810 273 93 122 455 1.438 1.039 487 457 825 394 413 814
2025/202611.336 678 270 874 1.092 1.539 1.360 1.859 701 1.269 1.139 555 0
Totale 44.076